Lipid and Atherosclerosis Unit, IMIBIC/Hospital Universitario Reina Sofía/Universidad de Córdoba, Córdoba, Spain.
CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
J Thromb Haemost. 2019 May;17(5):818-826. doi: 10.1111/jth.14420. Epub 2019 Mar 18.
Essentials Ceruloplasmin (CP) is an acute-phase reactant and a potential biomarker of atherothrombotic risk. We assessed associations between CP and venous thromboembolism (VTE) risk in 9933 individuals. Higher circulating CP but not CP-related genes were associated with greater incident VTE rates. Circulating CP could be considered a non-causal biomarker of VTE risk in the community. SUMMARY: Background Ceruloplasmin (CP) is an acute-phase reactant and a potential biomarker of atherothrombotic risk. We assessed the associations between CP, CP-associated genetic variants and incident venous thomboembolism (VTE) in the Atherosclerosis Risk in Communities study. Methods and results In an observational study, 9933 men and women aged 53-75 years without prevalent VTE were included in 1996-1998 and followed through 2011. Circulating CP was measured in stored blood samples obtained in 1996-1998. Polymorphisms rs11708215 and rs13072552, which have been previously associated with CP concentrations, were measured in 8439 participants. VTEs were identified from hospital discharge codes and validated by physician review of medical records and imaging reports. Over a mean of 10.5 years of follow-up, 376 cases of VTE were identified. The association between circulating CP, CP-associated polymorphisms and the incidence of VTE was estimated. After adjustment for traditional risk factors and biomarkers, higher concentrations of circulating CP were associated with greater incident VTE rates (hazard ratio 1.82, 95% confidence interval 1.12-2.95, comparing the 87.5-100th percentile with the bottom quartile). Both rs11708215 and rs13072552 were associated with CP concentrations but not with VTE risk. Conclusions Even though high CP concentrations were associated with an increased VTE risk, CP-associated genetic variants were not associated with a higher risk of VTE. Our results suggest that circulating CP concentrations may not be causally related to the risk of incident VTE.
铜蓝蛋白(CP)是一种急性期反应物,也是动脉血栓形成风险的潜在生物标志物。我们评估了 9933 个人的 CP 与静脉血栓栓塞(VTE)风险之间的关联。较高的循环 CP,但不是 CP 相关基因,与更高的 VTE 发生率相关。循环 CP 可被视为社区中 VTE 风险的非因果性生物标志物。
铜蓝蛋白(CP)是一种急性期反应物,也是动脉血栓形成风险的潜在生物标志物。我们评估了在社区动脉粥样硬化风险研究中 CP、CP 相关遗传变异与静脉血栓栓塞(VTE)事件之间的相关性。
在一项观察性研究中,1996-1998 年纳入了 9933 名年龄在 53-75 岁之间、无 VTE 既往史的男性和女性,并随访至 2011 年。1996-1998 年采集的储存血样中检测到循环 CP。在 8439 名参与者中测量了之前与 CP 浓度相关的 rs11708215 和 rs13072552 多态性。通过医院出院代码识别 VTE,并通过医生审查病历和影像学报告进行验证。在平均 10.5 年的随访期间,共发现 376 例 VTE。评估了循环 CP、CP 相关多态性与 VTE 发生率之间的关系。在调整了传统危险因素和生物标志物后,较高的循环 CP 浓度与较高的 VTE 发生率相关(风险比 1.82,95%置信区间 1.12-2.95,与第 87.5-100 百分位数与第 25 百分位数相比)。rs11708215 和 rs13072552 均与 CP 浓度相关,但与 VTE 风险无关。
尽管高 CP 浓度与 VTE 风险增加相关,但 CP 相关的遗传变异与更高的 VTE 风险无关。我们的结果表明,循环 CP 浓度可能与新发 VTE 风险无因果关系。